Adjuvant therapy with pegylated interferon α-2b versus observation in resected stage III melanoma:: final results of EORTC 18991, a randomised phase 3 trial

被引：0
|
作者：
Eggermont, A. M. M. [1 ]
Suciu, S. [1 ]
Santinami, M. [1 ]
Testori, A. [1 ]
Kruit, W. [1 ]
Marsden, J. [1 ]
Punt, C. J. A. [1 ]
Sales, F. [1 ]
Gore, M. [1 ]
Mckie, R. [1 ]
Kusic, V. [1 ]
Dummer, R. [1 ]
Musat, E. [1 ]
Spatz, A. [1 ]
Keilholz, U. [1 ]
机构：
[1] Erasmus Univ, Med Ctr, Dr Daniel Den Hoed Canc Ctr, NL-3000 DR Rotterdam, Netherlands
来源：
PIGMENT CELL & MELANOMA RESEARCH | 2008年 / 21卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：290 / 290
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma
    A. I. Daud
    C. Xu
    W.-J. Hwu
    P. Urbas
    S. Andrews
    N. E. Papadopoulos
    L. C. Floren
    A. Yver
    R. C. DeConti
    V. K. Sondak
    [J]. Cancer Chemotherapy and Pharmacology, 2011, 67 : 657 - 666
  • [22] Adjuvant use of interferon α2b is not justified in patients with stage IIb/III melanoma
    Bajetta, Emilio
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (01): : 4 - 5
  • [23] Adjuvant use of interferon α2b is not justified in patients with stage IIb/III melanoma
    Emilio Bajetta
    [J]. Nature Clinical Practice Oncology, 2008, 5 : 4 - 5
  • [24] Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group (vol 27, pg 2916, 2009)
    Bottomley
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4630 - 4630
  • [25] Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
    Patel, Poulam M.
    Suciu, Stefan
    Mortier, Laurent
    Kruit, Wim H.
    Robert, Caroline
    Schadendorf, Dirk
    Trefzer, Uwe
    Punt, Cornelis J. A.
    Dummer, Reinhard
    Davidson, Neville
    Becker, Juergen
    Conry, Robert
    Thompson, John A.
    Hwu, Wen-Jen
    Engelen, Kristel
    Agarwala, Sanjiv S.
    Keilholz, Ulrich
    Eggermont, Alexander M. M.
    Spatz, Alain
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (10) : 1476 - 1483
  • [26] Concurrent adjuvant radiotherapy and interferon-α2b for resected high risk stage III melanoma -: a retrospective single centre study
    Gyorki, DE
    Ainslie, J
    Joon, ML
    Henderson, MA
    Millward, M
    McArthur, GA
    [J]. MELANOMA RESEARCH, 2004, 14 (03) : 223 - 230
  • [27] EXTENDED SCHEDULE, ESCALATED DOSE TEMOZLOMIDE VERSUS DACARBAZINE IN STAGE IV MALIGNANT MELANOMA: FINAL RESULTS OF THE RANDOMISED PHASE III STUDY(EORTC 18032)
    Patel, P. M.
    Suciu, S.
    Mortier, L.
    Kruit, W.
    Robert, C.
    Schadendorf, D.
    Keilholz, U.
    Musat, E.
    Eggermont, A.
    Spatz, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 3 - 3
  • [28] Interferon-α-2b as an adjuvant therapy prolongs survival of patients with previously resected oral muscosal melanoma
    Wang, R.
    Jing, G.
    Lv, J.
    Song, H.
    Li, C.
    Wang, X.
    Xia, W.
    Wu, Y.
    Ren, G.
    Guo, W.
    [J]. GENETICS AND MOLECULAR RESEARCH, 2015, 14 (04) : 11944 - 11954
  • [29] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
    Eggermont, Alexander M. M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina, V
    Atkinson, Victoria G.
    Dalle, Stephane
    Haydon, Andrew M.
    Meshcheryakov, Andrey
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Giacomo, Anna Maria Di
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Lorigan, Paul C.
    van Akkooi, Alexander C. J.
    Krepler, Clemens
    Ibrahim, Nageatte
    Marreaud, Sandrine
    Kicinski, Michal
    Suciu, Stefan
    Robert, Caroline
    [J]. LANCET ONCOLOGY, 2021, 22 (05): : 643 - 654
  • [30] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    Kirkwood, John M.
    Tarhini, Ahmad A.
    Moschos, Stergios J.
    Panelli, Monica C.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (01): : 2 - 3
12345